Elicera Therapeutics announces participation in several industry and partnering conferences
Gothenburg, August 12, 2022 - Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next generation immuno-oncological treatments based on enhanced oncolytic viruses and CAR T-cells, today announced, that the company will attend the following industry and partnering meetings in 2022:· Cell Therapy Durability Response Summit August 22-23, 2022 – Boston, USA Elicera is sponsoring this event focusing on engineering strategies to deliver persistent, efficacious, safe cell therapy products. Senior Scientist, Tina Sarén, to present the iTANK-